|Day Low/High||90.05 / 91.11|
|52 Wk Low/High||58.59 / 96.95|
Many see the Fed as done for the year. Never assume. Read the words as they are written.
These themes are working despite the turmoil in Washington and slowing global growth.
I would add to them on any significant dips in the market.
The RMPIA is once again outpacing the S&P 500, Dow Jones Industrial Average and the Nasdaq Composite Index.
Deals that simply were unworkable four months ago because of price are now being done with alacrity.
One of pharma's biggest CEO's talks M&A action on the exchange.
The company is set to report earnings on Jan. 29, so traders have a couple of weeks to watch the action.
I would not be surprised if we see a bout of profit-taking in the near future given the sharpness of the recent rebound.
This is the kind of reversal that happens in a bull market.
Beaten-down Entercom Communications and Dynavax Technologies are off to good starts this year and should continue to improve.
The RMPIA index was up for the year, while the S&P 500, DJIA, Russell 2000 and Nasdaq all finished 2018 in the red.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
Pharma companies that have cash are looking at what has happened to this stock market and buying.
And it is happening not a moment too soon.
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
The big problem this market faces technically is that there isn't much support down to the lows hit on Dec. 24.
The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.
It can be disturbing to see various names lose value quickly on no news, but here is a method to take advantage of such moves.
Both names looked poised to go higher as soon as sentiment around the small biotech sector improves.
Celgene could be at a temporary low or it could be starting a new base pattern.
I tire of hearing that there has been a correction.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.